{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:07:38Z","timestamp":1770419258348,"version":"3.49.0"},"reference-count":269,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Therapeutic Targets"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1517\/14728222.8.3.221","type":"journal-article","created":{"date-parts":[[2004,5,27]],"date-time":"2004-05-27T10:52:41Z","timestamp":1085655161000},"page":"221-239","source":"Crossref","is-referenced-by-count":16,"title":["Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias"],"prefix":"10.1517","volume":"8","author":[{"given":"Lolita","family":"Banerji","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. martin_sattler@dfci.harvard.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. martin_sattler@dfci.harvard.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,2,25]]},"reference":[{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206091"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2000.0115"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200107000-00001"},{"key":"e_1_2_1_6_1","first-page":"8655","article-title":"Identification and characterization of an activating TrIcA deletion mutation in acute myeloid leukemia","volume":"20","author":"REUTHER GW","year":"2000","unstructured":"REUTHER GW, LAMBERT QT, CALIGIURI MA et al.: Identification and characterization of an activating TrIcA deletion mutation in acute myeloid leukemia. Ma Cell. Biol. (2000) 20:8655\u20138666.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.4.1355"},{"key":"e_1_2_1_8_1","first-page":"87","article-title":"Absence of mutations in the RET gene in acute myeloid leukemia","volume":"75","author":"VISSER M","year":"1997","unstructured":"VISSER M, HOFSTRA RM, STULP RP et al.: Absence of mutations in the RET gene in acute myeloid leukemia. Ann. Heinatol (1997) 75:87\u201390.","journal-title":"Ann. Heinatol"},{"key":"e_1_2_1_9_1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"NOWELL PC","year":"1960","unstructured":"NOWELL PC, HUNGERFORD DA: Chromosome studies on normal and leukemic human leukocytes. Natl. Cancer Inst. (1960) 25:85\u2013109.","journal-title":"Natl. Cancer Inst."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/306239a0"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/325631a0"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/315758a0"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/330386a0"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3541203"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/329851a0"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/325635a0"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_1_22_1","unstructured":"\u2022\u2022Report shows that irnatinib is a specificinhibitor for BCR-ABL and is effective in reducing colony formation in primary CML cells."},{"key":"e_1_2_1_23_1","first-page":"2965","article-title":"Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers","volume":"6","author":"DONATO NJ","year":"2000","unstructured":"DONATO NJ, TALPAZ M: Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers. Clin. Cancer Res. (2000) 6:2965\u20132966.","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02029-8"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.12.4947"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203698"},{"key":"e_1_2_1_28_1","doi-asserted-by":"crossref","unstructured":"BUCHDUNGER E CIOFFI CL LAW N et al.: Abl protein-tyrosine kinase inhibitor 5TI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. Phannacol Exp. Ther: (2000) 295:139\u2013145.","DOI":"10.1016\/S0022-3565(24)38879-2"},{"key":"e_1_2_1_29_1","first-page":"3319","article-title":"The selective tyrosine kinase inhibitor 5TI571 inhibits small cell lung cancer growth","volume":"6","author":"KRYSTAL GW","year":"2000","unstructured":"KRYSTAL GW, HONSAWEK S, LITZ J et al.: The selective tyrosine kinase inhibitor 5TI571 inhibits small cell lung cancer growth. Clin. Cancer Res. (2000) 6:3319\u20133326.","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.925"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp038130"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07671-7"},{"key":"e_1_2_1_35_1","doi-asserted-by":"crossref","unstructured":"SCHINDLER T BORNMANN W PELLICENA Petal.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289:1938\u20131942.","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_2_1_36_1","unstructured":"\u2022\u2022Important report on the mechanismof ABL tyrosine kinase inhibition by imatinib mesylate."},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"e_1_2_1_38_1","unstructured":"\u2022\u2022Comprehensive list of mutations that result in irnatinib mesylate resistance."},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.22.10282"},{"key":"e_1_2_1_40_1","first-page":"7587","article-title":"A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins","volume":"13","author":"MCWHIRTER JR","year":"1993","unstructured":"MCWHIRTER JR, GALASSO DL, WANG JY: A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Ma Cell. Biol. (1993) 13:7587\u20137595.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_41_1","unstructured":"\u2022Demonstrates the importance of the oligomerisation domain in BCR for activation of the ABL kinase."},{"key":"e_1_2_1_42_1","first-page":"4107","article-title":"Oligomerization of the Abl tyrosine kinase by the Ets protein Tel in human leukemia","volume":"16","author":"GOLUB TR","year":"1996","unstructured":"GOLUB TR, GOGA A, BARKER GF et al: Oligomerization of the Abl tyrosine kinase by the Ets protein Tel in human leukemia. MM. Cell. Biol. (1996) 16:4107\u20134116.","journal-title":"MM. Cell. Biol."},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00191-0"},{"key":"e_1_2_1_44_1","unstructured":"\u2022\u2022Study of the structural requirements forc-ABL activation."},{"key":"e_1_2_1_45_1","doi-asserted-by":"crossref","unstructured":"NAGAR B HANTSCHEL 0 YOUNG MA et al.: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 112:859\u2013871.","DOI":"10.1016\/S0092-8674(03)00194-6"},{"key":"e_1_2_1_46_1","unstructured":"\u2022\u2022Study of the structural requirements forc-ABL activation."},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.664"},{"key":"e_1_2_1_48_1","first-page":"840","article-title":"The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl","volume":"21","author":"ZHANG X","year":"2001","unstructured":"ZHANG X, SUBRAHMANYAM R, WONG R et al: The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Ma Cell. Biol. (2001) 21:840\u2013853.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(05)80094-7"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06319.x"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8153630"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.11.2393"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00074-0"},{"key":"e_1_2_1_54_1","unstructured":"\u2022Demonstrates the requirement of Gab2 for BCR-ABL-mediated myeloid leukaemia."},{"key":"e_1_2_1_55_1","first-page":"652","article-title":"Protein kinases as mediators of phosphoinositide 3-kinase signaling","volume":"57","author":"TOKER A","year":"2000","unstructured":"TOKER A: Protein kinases as mediators of phosphoinositide 3-kinase signaling. MM. Phannacol (2000) 57:652\u2013658.","journal-title":"MM. Phannacol"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.13.8347"},{"key":"e_1_2_1_57_1","unstructured":"\u2022\u2022This review focuses on PI3K and its role invarious cellular processes."},{"key":"e_1_2_1_58_1","first-page":"839","article-title":"The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR\/ABL and p210BCR\/ABL to the phosphatidylinosito1-3' kinase pathway","volume":"12","author":"SATTLER M","year":"1996","unstructured":"SATTLER M, SALGIA R, OKUDA K et al.: The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR\/ABL and p210BCR\/ABL to the phosphatidylinosito1-3' kinase pathway. Oncogene (1996) 12:839\u2013846.","journal-title":"Oncogene"},{"key":"e_1_2_1_59_1","first-page":"1107","article-title":"Activation of phosphatidylinositol 3-kinase in cells expressing Abl oncogene variants","volume":"11","author":"VARTICOVSKI L","year":"1991","unstructured":"VARTICOVSKI L, DALEY GQ, JACKSON P et al: Activation of phosphatidylinositol 3-kinase in cells expressing Abl oncogene variants. MM. Cell. Biol. (1991) 11:1107\u20131113.","journal-title":"MM. Cell. Biol."},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726"},{"key":"e_1_2_1_61_1","first-page":"5535","article-title":"Growth factor-mediated terminal differentiation of chronic myeloid leukemia","volume":"54","author":"BEDI A","year":"1994","unstructured":"BEDI A, GRIFFIN CA, BARBER JP et al:Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res. (1994) 54:5535\u20135538.","journal-title":"Cancer Res."},{"key":"e_1_2_1_62_1","first-page":"2038","volume":"83","author":"BEDI A","year":"1994","unstructured":"BEDI A, ZEHNBAUER BA, BARBER JPet al.: Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia. Blood (1994) 83:2038\u20132044.","journal-title":"BARBER JPet al.: Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia. Blood"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.20.6151"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80405-5"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80595-4"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00091-5"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.5049"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.20.11858"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90228-9"},{"key":"e_1_2_1_70_1","first-page":"1153","article-title":"Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene","volume":"65","author":"TYBULEWICZ VL","year":"1991","unstructured":"TYBULEWICZ VL, CRAWFORD CE, JACKSON PK et al: Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Ce\/\/(1991) 65:1153\u20131163.","journal-title":"Ce\/\/"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90012-N"},{"key":"e_1_2_1_72_1","first-page":"304","article-title":"DE LOS SANTOS K et al","volume":"24","author":"LI B","year":"2000","unstructured":"LI B, BOASTS, DE LOS SANTOS K et al.: Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat. Genet. (2000) 24:304\u2013308.","journal-title":"Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat. Genet."},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/376785a0"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90497-E"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/382272a0"},{"key":"e_1_2_1_76_1","first-page":"1728","article-title":"SH1 domain autophosphorylation of p210 BCR\/ABL is required for transformation but not growth factor independence","volume":"13","author":"PENDERGAST AM","year":"1993","unstructured":"PENDERGAST AM, GISHIZKY ML, HAVLIK MH et al: SH1 domain autophosphorylation of p210 BCR\/ABL is required for transformation but not growth factor independence. MM. Cell. Biol. (1993) 13:1728\u20131736.","journal-title":"MM. Cell. Biol."},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0398-280"},{"key":"e_1_2_1_78_1","first-page":"1553","article-title":"J: Activation of tyrosine kinase and microfilament-binding functions of c-Ab\/ by Bcr sequences in Bcr\/Ab\/fusion proteins","volume":"11","author":"MCWHIRTERJ WANG","year":"1991","unstructured":"MCWHIRTERJ, WANG J: Activation of tyrosine kinase and microfilament-binding functions of c-Ab\/ by Bcr sequences in Bcr\/Ab\/fusion proteins. Ma Cell. Biol. (1991) 11:1553\u20131565.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2226"},{"key":"e_1_2_1_80_1","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"DANHAUSER-RIEDL S","year":"1996","unstructured":"DANHAUSER-RIEDL S, WARMUTH M, DRUKER BJ et al: Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells. Cancer Res. (1996) 56:3589\u20133596.","journal-title":"Cancer Res"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020519"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000126200"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf562"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.811"},{"key":"e_1_2_1_86_1","first-page":"247","article-title":"Constitutive activation of Stat5 by the Bcr-Abl oncogene in chronic myelogenous leukemia","volume":"13","author":"SHUAI K","year":"1996","unstructured":"SHUAI K, HALPERN J, TENHOEVE J et al.: Constitutive activation of Stat5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene (1996) 13:247\u2013254.","journal-title":"Oncogene"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2277"},{"key":"e_1_2_1_88_1","first-page":"3871","article-title":"Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation","volume":"18","author":"ONISHI M","year":"1998","unstructured":"ONISHI M, NOSAKA T, MISAWA K et al.: Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. MM. Cell. Biol. (1998) 18:3871\u20133879.","journal-title":"MM. Cell. Biol."},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002094200"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(94)00198-S"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi973035t"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(96)00051-2"},{"key":"e_1_2_1_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/43459"},{"key":"e_1_2_1_94_1","unstructured":"\u2022Report demonstrated the potential role of superoxide in cell growth and transformation."},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.1069"},{"key":"e_1_2_1_96_1","unstructured":"\u2022\u2022This review focuses on PDGFR and its rolein development."},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206330"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000041501.01323.b9"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-1023fje"},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.23.13642"},{"key":"e_1_2_1_101_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2536956"},{"key":"e_1_2_1_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/35074588"},{"key":"e_1_2_1_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1995.tb20378.x"},{"key":"e_1_2_1_104_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M309986200"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.151"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2000.4896"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb05879.x"},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202694"},{"key":"e_1_2_1_109_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.16.7696"},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/378509a0"},{"key":"e_1_2_1_111_1","doi-asserted-by":"crossref","unstructured":"TOMASSON MH STERNBERG DW WILLIAMS IR et al.: Fatal myeloproliferation induced in mice by TEL\/PDGFRI3 expression depends on PDGFRI3 tyrosines 579\/581.1 Gin. Invest. (2000) 105:423\u2013432.","DOI":"10.1172\/JCI8902"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.23.6912"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3910"},{"key":"e_1_2_1_114_1","first-page":"6715","article-title":"Tyr-716 in the platelet-derived growth factor 13-receptor kinase insert is involved in GRB2 binding and Ras activation","volume":"14","author":"ARVIDSSON AK","year":"1994","unstructured":"ARVIDSSON AK, RUPP E, NANBERG E et al: Tyr-716 in the platelet-derived growth factor 13-receptor kinase insert is involved in GRB2 binding and Ras activation. Ma Cell. Biol. (1994) 14:6715\u20136726.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_115_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.48.30942"},{"key":"e_1_2_1_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05182.x"},{"key":"e_1_2_1_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.11.6889-6896.1993"},{"key":"e_1_2_1_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202705"},{"key":"e_1_2_1_119_1","first-page":"7867","article-title":"Nckl3 adapter regulates actin polymerization in NIH 3T3 fibroblasts in response to platelet-derived growth factor bb","volume":"20","author":"CHEN M","year":"2000","unstructured":"CHEN M, SHE H, KIM A et al: Nckl3 adapter regulates actin polymerization in NIH 3T3 fibroblasts in response to platelet-derived growth factor bb. Ma Cell. Biol. (2000) 20:7867\u20137880.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_120_1","unstructured":"HIWATARI M MASAHIRO T RYOJI H TERUAKI H MASAHIRO S: Mutation of c-KIT and platelet-derived growth factor receptor (PDGFR) genes in childhood acute myeloid leukemia and leukemic cell lines. Blood (2003):102: Abstract 3218."},{"key":"e_1_2_1_121_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_2_1_122_1","unstructured":"\u2022Publication reports on the novel FIP1L1-PDGFRa translocation and its sensitivity to imatinib and PKC412."},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_1_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2479"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00108-9"},{"key":"e_1_2_1_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"e_1_2_1_127_1","unstructured":"\u2022First report to publish the TEL-PDGFR fusion in CMML."},{"key":"e_1_2_1_128_1","first-page":"1758","article-title":"TEL\/platelet-derived growth factor receptor 13 activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle","volume":"2002","author":"DIEROV J","unstructured":"DIEROV J, XU Q, DIEROVA R et al: TEL\/platelet-derived growth factor receptor 13 activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood (2002) 99: 1758-1765.","journal-title":"Blood"},{"key":"e_1_2_1_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.11.4271"},{"key":"e_1_2_1_130_1","first-page":"3592","article-title":"Fusion of H4\/D105170 to the platelet-derived growth factor receptor 13 in BCR-ABL-negative myeloproliferative disorders with a t(5;10) (q33;q21)","volume":"60","author":"KULKARNI S","year":"2000","unstructured":"KULKARNI S, HEATH C, PARKER S et al: Fusion of H4\/D105170 to the platelet-derived growth factor receptor 13 in BCR-ABL-negative myeloproliferative disorders with a t(5;10) (q33;q21). Cancer Res. (2000) 60:3592\u20133598.","journal-title":"Cancer Res"},{"key":"e_1_2_1_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1150"},{"key":"e_1_2_1_132_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0165"},{"key":"e_1_2_1_133_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8902"},{"key":"e_1_2_1_134_1","unstructured":"HEINRICH MC GIESE NA SCHITTENHELM M: MLN518 a potent FLT3 inhibitor displays synergistic effects with cytarabine and daunorubicin on FLT3 ITD leukemia cell lines. Blood (2003):102: Abstract 330."},{"key":"e_1_2_1_135_1","unstructured":"MENEZES DLS WIESMANN M VORA J et al.: Preclinical pharmacology of FLT3 kinase inhibitor CHIR258LC in the treatment of xenograft tumors of human acute myelogenous leukemia. Blood (2003):102: Abstract 1403."},{"key":"e_1_2_1_136_1","unstructured":"CAIN J TOMASSON MH: Complete remission but not cure of myeloproliferative disease by SU11657 in a murine TEL\/PDGFRI3 bone marrow transplant model. Blood (2003):102: Abstract 2436."},{"key":"e_1_2_1_137_1","doi-asserted-by":"crossref","unstructured":"ROSNET 0 MATTEI MG MARCHETTO S et al.: Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Cenomics (1991) 9:380\u2013385.","DOI":"10.1016\/0888-7543(91)90270-O"},{"key":"e_1_2_1_138_1","first-page":"1143","article-title":"A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations","volume":"65","author":"MATTHEWS W","year":"1991","unstructured":"MATTHEWS W, JORDAN CT, WIEGAND GW et al.: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Ce\/\/(1991) 65:1143\u20131152.","journal-title":"Ce\/\/"},{"key":"e_1_2_1_139_1","doi-asserted-by":"crossref","unstructured":"ROSNET 0 SCHIFF C PEBUSQUE MJ et al.: Human FLT3\/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 82:1110\u20131119.","DOI":"10.1182\/blood.V82.4.1110.1110"},{"key":"e_1_2_1_140_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.2.459"},{"key":"e_1_2_1_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/368643a0"},{"key":"e_1_2_1_142_1","doi-asserted-by":"crossref","unstructured":"LYMAN SD JAMES L VANDEN BOS T et al.: Molecular cloning of a ligand for the flt3\/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell (1993) 75:1157\u20131167.","DOI":"10.1016\/0092-8674(93)90325-K"},{"key":"e_1_2_1_143_1","doi-asserted-by":"crossref","unstructured":"BIRG F COURCOUL M ROSNET 0 et al.: Expression of the FMS\/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood (1992) 80:2584\u20132593.","DOI":"10.1182\/blood.V80.10.2584.2584"},{"key":"e_1_2_1_144_1","doi-asserted-by":"publisher","DOI":"10.1159\/000134046"},{"key":"e_1_2_1_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.3987.bloodjournal88103987"},{"key":"e_1_2_1_146_1","first-page":"378","article-title":"Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children","volume":"24","author":"MCKENNA HJ","year":"1996","unstructured":"MCKENNA HJ, SMITH FO, BRASEL K et al: Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Exp. Hematol (1996) 24:378\u2013385.","journal-title":"Exp. Hematol"},{"key":"e_1_2_1_147_1","unstructured":"\u2022Describes the phenotype of mice with F\/t3 gene disruption."},{"key":"e_1_2_1_148_1","doi-asserted-by":"publisher","DOI":"10.1089\/152581600750062408"},{"key":"e_1_2_1_149_1","first-page":"6572","article-title":"Mitogenic signalling and substrate specificity of the F1k2\/F1t3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells","volume":"13","author":"DOSIL M","year":"1993","unstructured":"DOSIL M, WANG S, LEMISCHKA IR: Mitogenic signalling and substrate specificity of the F1k2\/F1t3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Ma Cell. Biol. (1993) 13:6572\u20136585.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401527"},{"key":"e_1_2_1_151_1","first-page":"1755","article-title":"Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine F1t3 receptor tyrosine kinase","volume":"1994","author":"ROTTAPEL R","unstructured":"ROTTAPEL R, TURCK CW, CASTERAN N et al: Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine F1t3 receptor tyrosine kinase. Oncogene (1994) 9: 1755-1765.","journal-title":"Oncogene"},{"key":"e_1_2_1_152_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.5.719"},{"key":"e_1_2_1_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90167-1"},{"key":"e_1_2_1_154_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3489"},{"key":"e_1_2_1_155_1","first-page":"1901","article-title":"Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia","volume":"2004","author":"OZEKI K","unstructured":"OZEKI K, KIYOI H, HIROSE Y et al: Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood (2004) 103: 1901-1908.","journal-title":"Blood"},{"key":"e_1_2_1_156_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3589"},{"key":"e_1_2_1_157_1","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"1996","author":"NAKAO M","unstructured":"NAKAO M, YOKOTA S, IWAI T et al: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 10: 1911-1918.","journal-title":"Leukemia"},{"key":"e_1_2_1_158_1","first-page":"1447","article-title":"Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia","volume":"11","author":"KIYOI H","year":"1997","unstructured":"KIYOI H, NAOE T, YOKOTA S et al: Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia (1997) 11:1447\u20131452.","journal-title":"Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia"},{"key":"e_1_2_1_159_1","doi-asserted-by":"crossref","unstructured":"MESHINCHI S WOODS WG STIRE WALT DL et al.: Prevalence and prognostic significance of F1t3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 97:89\u201394.","DOI":"10.1182\/blood.V97.1.89"},{"key":"e_1_2_1_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401731"},{"key":"e_1_2_1_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01284.x"},{"key":"e_1_2_1_162_1","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study","volume":"61","author":"WHITMAN SP","year":"2001","unstructured":"WHITMAN SP, ARCHER KJ, FENG L et al.: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. (2001) 61:7233\u20137239.","journal-title":"Cancer Res"},{"key":"e_1_2_1_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.310"},{"key":"e_1_2_1_164_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02850.x"},{"key":"e_1_2_1_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.8.2434"},{"key":"e_1_2_1_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402199"},{"key":"e_1_2_1_167_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.885"},{"key":"e_1_2_1_168_1","first-page":"S27\u2013S30","article-title":"FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy","volume":"48","author":"NAOE T","year":"2001","unstructured":"NAOE T, KIYOE H, YAMAMOTO Y et al.: FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother. Pliarmacol (2001) 48:S27\u2013S30.","journal-title":"Cancer Chemother. Pliarmacol"},{"key":"e_1_2_1_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00070-3"},{"key":"e_1_2_1_170_1","first-page":"721a","article-title":"FLT3 antagonism as a strategy for the treatment of acute myeloid leukemia (AML)","volume":"98","author":"YU J-C, APATIRA M, LI J","year":"2001","unstructured":"YU J-C, APATIRA M, LI J et al: FLT3 antagonism as a strategy for the treatment of acute myeloid leukemia (AML). Blood (2001) 98:721a.","journal-title":"Blood"},{"key":"e_1_2_1_171_1","first-page":"118a","article-title":"FLT3-targeted tyrosine kinase inhibitors inhibit proliferation, induce apoptosis, and improve survival in a murine leukemia model utilizing FLT3\/ITD-transformed cells","volume":"89","author":"ALLEBACH J","year":"2001","unstructured":"ALLEBACH J, LEVIS M, FAI-TSE K et al.: FLT3-targeted tyrosine kinase inhibitors inhibit proliferation, induce apoptosis, and improve survival in a murine leukemia model utilizing FLT3\/ITD-transformed cells. Blood (2001) 89:118a.","journal-title":"Blood"},{"key":"e_1_2_1_172_1","first-page":"721a","article-title":"FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts M vitro and in vivo","author":"LEVIS MJ","year":"2001","unstructured":"LEVIS MJ, ALLEBACH J, TSE KF et al.: FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts M vitro and in vivo. Blood (2001):721a.","journal-title":"Blood"},{"key":"e_1_2_1_173_1","unstructured":"O'FARRELL A ABRAMS T YUEN H et al.: SUGEN compounds 5U5416 and SU11248 inhibit F1t3 activity: therapeutic application in AML. Blood (2001) 89:118a."},{"key":"e_1_2_1_174_1","first-page":"838a","article-title":"FARRELL A, SMOLICH B et al: 5U5416 and 5U5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells","volume":"89","author":"YEE K O&apos","year":"2001","unstructured":"YEE K, O'FARRELL A, SMOLICH B et al: 5U5416 and 5U5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells. Blood (2001) 89:838a.","journal-title":"Blood"},{"key":"e_1_2_1_175_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910430519"},{"key":"e_1_2_1_176_1","first-page":"1485","article-title":"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C","volume":"19","author":"PROPPER DJ","year":"2001","unstructured":"PROPPER DJ, MCDONALD AC, MAN A et al.: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Clin. Oncol. (2001) 19:1485\u20131492.","journal-title":"Clin. Oncol."},{"key":"e_1_2_1_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00069-7"},{"key":"e_1_2_1_178_1","doi-asserted-by":"publisher","DOI":"10.1038\/320415a0"},{"key":"e_1_2_1_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90301-T"},{"key":"e_1_2_1_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90302-U"},{"key":"e_1_2_1_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90300-4"},{"key":"e_1_2_1_182_1","doi-asserted-by":"publisher","DOI":"10.1038\/335088a0"},{"key":"e_1_2_1_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90020-7"},{"key":"e_1_2_1_184_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_1_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70079-4"},{"key":"e_1_2_1_186_1","doi-asserted-by":"publisher","DOI":"10.1038\/1209"},{"key":"e_1_2_1_187_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.4.1609"},{"key":"e_1_2_1_188_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00370.x"},{"key":"e_1_2_1_189_1","doi-asserted-by":"crossref","unstructured":"THARP MD LONGLEY BJ Jr: Mastocytosis. Dermatol. Clin. (2001) 19:679-696 viii-ix.","DOI":"10.1016\/S0733-8635(05)70308-9"},{"key":"e_1_2_1_190_1","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:22:2:175"},{"key":"e_1_2_1_191_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_2_1_192_1","unstructured":"KANAKURA Y FURITSU T TSUJIMURA T et al.: Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia (1994) 8\\(Suppl. 1):518\u2013522."},{"key":"e_1_2_1_193_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116761"},{"key":"e_1_2_1_194_1","first-page":"1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to 5TI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"2002","author":"MA Y","unstructured":"MA Y, ZENG S, METCALFE DD et al.: The c-KIT mutation causing human mastocytosis is resistant to 5TI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood (2002) 99: 1741-1744.","journal-title":"Blood"},{"key":"e_1_2_1_195_1","doi-asserted-by":"crossref","unstructured":"NAKATA Y KIMURA A KATOH 0 et al.: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br. J. Haematol. (1995) 91:661\u2013663.","DOI":"10.1111\/j.1365-2141.1995.tb05364.x"},{"key":"e_1_2_1_196_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206587"},{"key":"e_1_2_1_197_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.11.2962.2962"},{"key":"e_1_2_1_198_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01449.x"},{"key":"e_1_2_1_199_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.726"},{"key":"e_1_2_1_200_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02655.x"},{"key":"e_1_2_1_201_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb07784.x"},{"key":"e_1_2_1_202_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409073786"},{"key":"e_1_2_1_203_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/19.6.1267"},{"key":"e_1_2_1_204_1","first-page":"3043","article-title":"The SteelAW transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor","volume":"11","author":"ROTTAPEL R","year":"1991","unstructured":"ROTTAPEL R, REEDIJK M, WILLIAMS DE et al.: The SteelAW transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Ma Cell. Biol. (1991) 11:3043\u20133051.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)31518-1"},{"key":"e_1_2_1_206_1","first-page":"3350","article-title":"Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand","volume":"13","author":"YI T","year":"1993","unstructured":"YI T, IHLE JN: Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. MM. Cell. Biol. (1993) 13:3350\u20133358.","journal-title":"MM. Cell. Biol."},{"key":"e_1_2_1_207_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M211726200"},{"key":"e_1_2_1_208_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.9.5915"},{"key":"e_1_2_1_209_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.43.27450"},{"key":"e_1_2_1_210_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202929"},{"key":"e_1_2_1_211_1","first-page":"4660","article-title":"Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PPl","volume":"58","author":"KRYSTAL GW","year":"1998","unstructured":"KRYSTAL GW, DEBERRY CS, LINNEKIN D et al.: Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PPl. Cancer Res. (1998) 58:4660\u20134666.","journal-title":"Cancer Res."},{"key":"e_1_2_1_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37564-6"},{"key":"e_1_2_1_213_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.2.678"},{"key":"e_1_2_1_214_1","doi-asserted-by":"crossref","unstructured":"NISHIDA K YOSHIDA Y ITOH M et al.: Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors. Blood(1999) 93:1809-1816. zoo. BRIZZI MF ZINI MG ARONICA MG et al.: Convergence of signaling by interleukin-3 granulocyte-macrophage colony-stimulating factor and mast cell growth factor on JAK2 tyrosine kinase. Biol. Chem. (1994) 269:31680\u201331684.","DOI":"10.1016\/S0021-9258(18)31749-6"},{"key":"e_1_2_1_215_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.9.3688.bloodjournal8793688"},{"key":"e_1_2_1_216_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"e_1_2_1_217_1","first-page":"385","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"PARGANAS E","year":"1998","unstructured":"PARGANAS E, WANG D, STRAVOPODIS D et al.: Jak2 is essential for signaling through a variety of cytokine receptors. Ce\/\/(1998) 93:385\u2013395.","journal-title":"Ce\/\/"},{"key":"e_1_2_1_218_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/21.9.2159"},{"key":"e_1_2_1_219_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3410211"},{"key":"e_1_2_1_220_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00017a026"},{"key":"e_1_2_1_221_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204877"},{"key":"e_1_2_1_222_1","first-page":"2089","article-title":"SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain","volume":"18","author":"KOZLOWSKI M","year":"1998","unstructured":"KOZLOWSKI M, LAROSE L, LEE F et al.: SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Ma Cell. Biol. (1998) 18:2089\u20132099.","journal-title":"Ma Cell. Biol."},{"key":"e_1_2_1_223_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.3.1111"},{"key":"e_1_2_1_224_1","doi-asserted-by":"crossref","unstructured":"PAULSON RE VESELY S SIMINOVITCH KA et al.: Signalling by the W\/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp 1. Nat. Genet. (1996) 13:309\u2013315.","DOI":"10.1038\/ng0796-309"},{"key":"e_1_2_1_225_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.24.7311"},{"key":"e_1_2_1_226_1","unstructured":"\u2022Describes the phenotype of mice with SHIP1 gene disruption."},{"key":"e_1_2_1_227_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb06104.x"},{"key":"e_1_2_1_228_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)31874-4"},{"key":"e_1_2_1_229_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.23.14192"},{"key":"e_1_2_1_230_1","first-page":"1583","article-title":"Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells","volume":"9","author":"BRIZZI ME BLECHMAN JM, CAVALLONI G et al","year":"1994","unstructured":"BRIZZI ME BLECHMAN JM, CAVALLONI G et al: Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells. Oncogene (1994) 9:1583\u20131589.","journal-title":"Oncogene"},{"key":"e_1_2_1_231_1","doi-asserted-by":"publisher","DOI":"10.1006\/smim.2000.0222"},{"key":"e_1_2_1_232_1","unstructured":"\u2022\u2022This review focuses on phosphatases andtheir role in immune cells."},{"key":"e_1_2_1_233_1","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase M vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"BUCHDUNGER E","year":"1996","unstructured":"BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Inhibition of the Abl protein-tyrosine kinase M vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56:100\u2013104.","journal-title":"Cancer Res"},{"key":"e_1_2_1_234_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404"},{"key":"e_1_2_1_235_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204704"},{"key":"e_1_2_1_236_1","first-page":"4244","article-title":"Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases","volume":"62","author":"WISNIEWSKI D","year":"2002","unstructured":"WISNIEWSKI D, LAMBEK CL, LIU C et al.: Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. (2002) 62:4244\u20134255.","journal-title":"Cancer Res."},{"key":"e_1_2_1_237_1","first-page":"3660","article-title":"Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells","volume":"61","author":"KRYSTAL GW","year":"2001","unstructured":"KRYSTAL GW, HONSAWEK S, KIEWLICH D et al.: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res. (2001) 61:3660\u20133668.","journal-title":"Cancer Res."},{"key":"e_1_2_1_238_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1413"},{"key":"e_1_2_1_239_1","first-page":"6106","article-title":"Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation","volume":"54","author":"KOVALENKO M","year":"1994","unstructured":"KOVALENKO M, GAZIT A, BOHMER A et al.: Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. (1994) 54:6106\u20136114.","journal-title":"Cancer Res."},{"key":"e_1_2_1_240_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171251798"},{"key":"e_1_2_1_241_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.862301"},{"key":"e_1_2_1_242_1","unstructured":"\u2022\u2022Useful introduction to RNAi technology."},{"key":"e_1_2_1_243_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1685"},{"key":"e_1_2_1_244_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt915"},{"key":"e_1_2_1_245_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4763"},{"key":"e_1_2_1_246_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2001.n.007"},{"key":"e_1_2_1_247_1","unstructured":"\u2022Investigates the potential clinical application of ribozymes against human cancers."},{"key":"e_1_2_1_248_1","unstructured":"NISHIUCHI R YQ WEIGEL B KERSEY JH: The geldanamycin derivative 17-AAG an inhibitor of the molecular chaperone heat shock protein 90 targets FLT3 and other protein kinases in human leukemia cells. Blood (2003):102: Abstract 2308."},{"key":"e_1_2_1_249_1","first-page":"4483","article-title":"FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases","volume":"9","author":"YAO Q","year":"2003","unstructured":"YAO Q, NISHIUCHI R, LI Q et al: FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin. Cancer Res. (2003) 9:4483\u20134493.","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_1_250_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0729"},{"key":"e_1_2_1_251_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3359"},{"key":"e_1_2_1_252_1","first-page":"1871","article-title":"A Phase I trial of the farnesyl transferase inhibitor 5CH66336: evidence for biological and clinical activity","volume":"60","author":"ADJEI AA","year":"2000","unstructured":"ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Phase I trial of the farnesyl transferase inhibitor 5CH66336: evidence for biological and clinical activity. Cancer Res. (2000) 60:1871\u20131877.","journal-title":"Cancer Res"},{"key":"e_1_2_1_253_1","first-page":"535","article-title":"Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies","volume":"9","author":"RAVANDI F","year":"2003","unstructured":"RAVANDI F, TALPAZ M, ESTROV Z: Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin. Cancer Res. (2003) 9:535\u2013550.","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_1_254_1","first-page":"1207","article-title":"Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue","volume":"45","author":"SEYNAEVE CM","year":"1994","unstructured":"SEYNAEVE CM, KAZANIETZ MG, BLUMBERG PM et al.: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. MM. Pharmacol (1994) 45:1207\u20131214.","journal-title":"MM. Pharmacol"},{"key":"e_1_2_1_255_1","first-page":"3980","article-title":"The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients","volume":"59","author":"THAVASU P","year":"1999","unstructured":"THAVASU P, PROPPER D, MCDONALD A et al.: The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res. (1999) 59:3980\u20133984.","journal-title":"Cancer Res"},{"key":"e_1_2_1_256_1","first-page":"2419","article-title":"Wortmannin, a potent and selective inhibitor of phosphatidylinosito1-3-kinase","volume":"54","author":"POWIS G","year":"1994","unstructured":"POWIS G, BONJOUKLIAN R, BERGGREN MM et al: Wortmannin, a potent and selective inhibitor of phosphatidylinosito1-3-kinase. Cancer Res. (1994) 54:2419\u20132423.","journal-title":"Cancer Res"},{"key":"e_1_2_1_257_1","doi-asserted-by":"crossref","unstructured":"VLAHOS CJ MATTER WE HUI KY et al.: A specific inhibitor of phosphatidylinositol 3-kinase 2-(4-morpholiny1)-8-pheny1-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. (1994) 269:5241\u20135248.","DOI":"10.1016\/S0021-9258(17)37680-9"},{"key":"e_1_2_1_258_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0936"},{"key":"e_1_2_1_259_1","doi-asserted-by":"crossref","unstructured":"PANDEY A VOLKOTS DL SEROOGY JM et al.: Identification of orally active potent and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.' Med. Chem. (2002) 45:3772\u20133793.","DOI":"10.1021\/jm020143r"},{"key":"e_1_2_1_260_1","unstructured":"AHN JY KK SMALL D: The FLT3 receptor tyrosine kinase inhibitor CEP5214 induces apoptotic cell death through down-regulation of Mc11. Blood (2003)102: Abstract 4501."},{"key":"e_1_2_1_261_1","unstructured":"BROWN PA MS BERNSTEIN ID ARCECI RJ SMALL D: CEP-701 and CEP-5214 FLT3 tyrosine kinase inhibitors are selectively cytotoxic to pediatric AML blasts with FLT3 internal tandem duplications. Blood (2003):102: Abstract 2202."},{"key":"e_1_2_1_262_1","first-page":"1247","article-title":"Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups","volume":"96","author":"SANZ MA","year":"2000","unstructured":"SANZ MA, LO COCO F, MARTIN G et al.: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood(2000) 96:1247\u20131253.","journal-title":"Blood"},{"key":"e_1_2_1_263_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.82"},{"key":"e_1_2_1_264_1","unstructured":"ABRAMS TJ LEE LB MURRAY LJ et al.: SU11248 inhibits KIT and platelet-derived growth factor receptor 13 in preclinical models of human small cell lung cancer. MM. Cancer The]: (2003) 2:471\u2013478."},{"key":"e_1_2_1_265_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.08.055"},{"key":"e_1_2_1_266_1","doi-asserted-by":"crossref","unstructured":"WARMUTH M SIMON N MITINA 0 et al.: Dual-specific Src and Abl kinase inhibitors PP1 and CGP76030 inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood (2003) 101:664\u2013672.","DOI":"10.1182\/blood-2002-01-0288"},{"key":"e_1_2_1_267_1","unstructured":"SIMON N SC HALLEK MJ: The dual-specific Src and Abl kinase inhibitor (SAKI) CGP76030 overcomes imatinib mesylate resistance in murine bone marrow cells transformed by Bcr-Abl. Blood (2003)102. Abstract 3199."},{"key":"e_1_2_1_268_1","unstructured":"O'HARE TSE ABDULLAH OM DEININGER MW et al: Potent inhibition of imatinib-resistant variants of Bcr-Abl by a novel dual selective Src\/Abl kinase inhibitor AP23464: implications for CML therapy. Blood (2003) 102. Abstract 59."},{"key":"e_1_2_1_269_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.12.4370"},{"key":"e_1_2_1_270_1","doi-asserted-by":"crossref","unstructured":"GOLUB TR BARKER GE LOVETT M et al.: Fusion of PDGF receptor 13 to a novel ets-like gene tel in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 77:307\u2013316.","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"e_1_2_1_271_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2518"}],"container-title":["Expert Opinion on Therapeutic Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14728222.8.3.221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:14:36Z","timestamp":1770376476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14728222.8.3.221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":269,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1517\/14728222.8.3.221"],"URL":"https:\/\/doi.org\/10.1517\/14728222.8.3.221","relation":{},"ISSN":["1472-8222","1744-7631"],"issn-type":[{"value":"1472-8222","type":"print"},{"value":"1744-7631","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}